The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Apr. 07, 2026

Filed:

Dec. 14, 2020
Applicant:

Merck Sharp & Dohme Llc, Rahway, NJ (US);

Inventors:

Michelle Machacek, Belmont, MA (US);

Michael D. Altman, Needham, MA (US);

Chunghui Huang, Arlington, MA (US);

Michael H. Reutershan, Brighton, MA (US);

David L. Sloman, Newton, MA (US);

Phieng Siliphaivanh, Newton Highlands, MA (US);

Sebastian E. Schneider, Cambridge, MA (US);

Charles S. Yeung, Dedham, MA (US);

David J. Witter, Toronto, CA;

Craig R. Gibeau, Northborough, MA (US);

Yingchun Ye, Belmont, MA (US);

Assignee:

Merck Sharp & Dohme LLC, Rahway, NJ (US);

Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
C07D 401/14 (2006.01); C07D 405/14 (2006.01); C07D 413/14 (2006.01); C07D 451/04 (2006.01); C07D 471/04 (2006.01); C07D 487/04 (2006.01); C07D 498/08 (2006.01);
U.S. Cl.
CPC ...
C07D 401/14 (2013.01); C07D 405/14 (2013.01); C07D 413/14 (2013.01); C07D 451/04 (2013.01); C07D 471/04 (2013.01); C07D 487/04 (2013.01); C07D 498/08 (2013.01);
Abstract

The present invention provides a compound of Formula (I) and the pharmaceutically acceptable salts, esters, and prodrugs thereof, which are PRMT5 inhibitors. Also provided are methods of making compounds of Formula I, pharmaceutical compositions comprising compounds of Formula I, and methods of using these compounds to treat cancer, sickle cell, and hereditary persistence of foetal hemoglobin (HPFH) mutations.


Find Patent Forward Citations

Loading…